基因生物标志物在NMIBC复发预测的新进展  

New Advances in the Prediction of NMIBC Recurrence by Genetic Biomarkers

作　　者：靳永胜[1] 郝亮亮 赵家伟 刘宇坤 霍彦名 钟亮 梁子龙 

机构地区：[1]延安大学附属医院泌尿外科,陕西 延安 [2]延安大学医学院,陕西 延安 [3]西安医学院研究生工作部,陕西 西安

出　　处：《临床医学进展》2023年第6期10534-10541,共8页Advances in Clinical Medicine

摘　　要：膀胱癌是泌尿生殖系统最常见的恶性肿瘤之一,在泌尿生殖系统的发病率和复发率较高。非肌层浸润性膀胱癌是一种与高复发率和高进展相关的膀胱癌亚型。所以在泌尿外科的诊疗过程中对于非肌层浸润性膀胱癌的复发预测显得尤为重要。目前预测非肌层浸润性膀胱癌复发和进展的工具是基于临床和组织病理学标记物的评分系统,这可能导致部分患者不能获得更准确以及个性化的复诊指导。新型基因生物标志物如启动子基因、尿液mRNA、DNA甲基化水平等非侵入性复发预测方法具有高敏感性、个体化等特点而在非肌层浸润性膀胱癌复发预测中具有更大优势。Bladder cancer is one of the most common malignant tumors in the genitourinary system, with a high incidence and recurrence rate in the genitourinary system. Non-muscular invasive bladder cancer is a bladder cancer subtype associated with a high recurrence rate and high progression. Therefore, the prediction of recurrence of non-muscular invasive bladder cancer in the process of diagnosis and treatment of urology is particularly important. Current tools for predicting the re-currence and progression of non-muscular invasive bladder cancer are scoring systems based on clinical and histopathological markers, which may result in some patients not receiving more accu-rate and personalized follow-up guidance. Novel gene biomarkers such as promoter genes, urine mRNA, DNA methylation levels and other non-invasive recurrence prediction methods have the characteristics of high sensitivity and personalization, and have greater advantages in the predic-tion of recurrence of non-muscle layer invasive bladder cancer.

关 键 词：非肌层浸润性膀胱癌 复发预测 基因生物标志物 

分 类 号：R73[医药卫生—肿瘤]